SFEBES2014 Oral Communications Clinical (6 abstracts)
1University of Cambridge, Cambridge, UK; 2Addenbrookes Hospital, Cambridge, UK; 3University Hospitals of Leicester, Leicester, UK.
Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about functionality of lesions (e.g. residual adenoma vs post-surgical scar tissue) and cannot reliably identify all microadenomas.
We hypothesised that i) imaging with the PET ligand 11C-methionine, which is taken up at sites of peptide/protein synthesis, would permit more reliable identification of functioning pituitary adenoma and ii) co-registration of PETCT with volume MRI (MetPETCTMRI) would yield more accurate anatomical localisation of 11C-methionine uptake.
80 scans were performed in our centre between 2010 and 2013. MetPETCTMRI was found to provide additional useful information in the following scenarios:
(A) Distinguishing residual functioning tumour from inactive or scar tissue post pituitary surgery (Figs 1 and 2) or medical therapy (e.g. cabergoline in prolactinoma) (n=29)
(B) Demonstrating medical therapeutic effects through significant reduction of tracer uptake post- compared to pre-treatment (Fig. 3) (n=15).